SHANGHAI, April 2, 2024 /PRNewswire/ -- YolTech Therapeutics announced that the first patient has been dosed with YOLT-101, the company's in vivo genome editing candidate being developed as a single ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results